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a  b  s  t  r  a  c  t
Radiotherapy  is  essential  for  the  treatment  of  oral  cancer,  especially  in  advanced  cases.  There  has  been
marked  progress  in this  ﬁeld  due  to  the  prevalence  of  intensity-modiﬁed  radiation  therapy  and  intro-
duction  of  particle  radiotherapy  using  protons  and  carbon-ions.  However,  these  treatments  are  stilleywords:
ral cancer
adiotherapy
oron neutron capture therapy
non-selective.  Boron  neutron  capture  therapy  (BNCT)  is  a unique  modality  in which  neutron  beams
destroy  only  boron  compound-bearing  tumor  cells  while  leaving  the  surrounding  normal  tissues  intact.
Thus,  BNCT  is  a selective  form  of radiotherapy,  if  high  tumor/normal  tissue  ratio  in boron  concentration
could  be  achieved.  The  principle  of  BNCT,  and  the  basic  study  of  the  mechanism  by  which  BNCT  exerts
antitumor  effects  using  oral  squamous  cell carcinoma  (SCC)  cells  and  oral  SCC  xenografts  in  mice are
described.© 2012 Japanese Stomatological Society. Published by Elsevier Ltd. All rights reserved.
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. Introduction
Oral cancers account for 30% of head and neck cancers and
reatment is dependent on the stage of the disease [1]. In stages
 and II, either surgery or therapy with external or internal irra-
iation is recommended. In stages III and IV, radiochemotherapy
s  recommended as a ﬁrst step. Thereafter, remaining tumors can
e removed by surgery [2]. In advanced cases, however, surgi-
al treatment causes severe cosmetic and functional disturbance,
owering quality of life. Radiotherapy is usually applied to tumors
lone or in combination with chemotherapy [3]. Indeed, the best
tudied concurrent chemoradiotherapy regimen involves radiation
positive margins, extracapsular nodal extension, lymphovascular
invasion, and perineural invasion (Fig. 1) [2,4]. It was  also reported
that cetuximab, an IgG1 monoclonal antibody against the ligand-
binding domain of epidermal growth factor, enhanced the cytotoxic
effects of radiation in squamous cell carcinoma (SCC) [5,6]. Thus,
radiotherapy is essential for the treatment of oral cancer.
The  radiotherapeutic management of oral cancer has changed
signiﬁcantly over the past 10 years, as intensity-modulated radia-
tion therapy (IMRT) has become the de facto standard treatment
[7,8]. In contrast to conventional radiotherapy, particle therapy
using carbon-ions or protons is also gaining importance worldwidend cisplatin, and is well-established as a standard of care in the
anagement of patients with unresectable head and neck can-
er, and oropharyngeal cancer and post-operative patients with
∗ Corresponding author. Tel.: +81 6 6879 2941; fax: +81 6 6879 2170.
E-mail  address: yura@dent.osaka-u.ac.jp (Y. Yura).
348-8643/$ – see front matter ©  2012 Japanese Stomatological Society. Published by Els
ttp://dx.doi.org/10.1016/S1348-8643(12)00046-8[9,10]. Compared with photons such as X-rays and gamma  rays,
the in-depth dose distribution of particles allows a more accurate
administration, resulting in an increased therapeutic ratio (Fig. 2).
Nevertheless, it remains unclear, mainly because of the absence of
randomized trials, whether particle therapy is superior to radio-
therapy with photons in cases of head and neck cancer.
In  spite of these developments, in principle, radiotherapy is still
non-selective. Although the effect is dependent on the dose, most
evier Ltd. All rights reserved.
10 Y.  Yura, Y. Fujita / Oral Science Int
Resect able   
Unres ecta ble  
Stage I/II  
Stage III/IV  
Surgery 
Radiotherapy  
Dista nt   
metastasis   
No  distant   
metastasis   
Chem ora dioth erap y  
Chem oth era py 
Surg ery or  
Chem ora dioth erapy  
Recurr enc e, 
Risk  fact ors  
Fig. 1. Treatment plan for oral cancer with surgery, radiation and chemotherapy. In
stages I and II, either surgery or treatment with external or internal irradiation is rec-
ommended. In stages III and IV, radiochemotherapy is recommended as the ﬁrst step.
Thereafter, remaining tumors can be removed by surgery. Usually, radiotherapy is
applied to tumors singly or in combination with chemotherapy.
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iig. 2. Types of radiation. X-rays, gamma  rays, protons, carbon-ions and neutrons
re  used for cancer therapy. LET, linear energy transfer.
ells exposed to radiation are damaged in a similar fashion. In this
espect, boron neutron capture therapy (BNCT) is unique in its
electivity in appropriate conditions [11–13]. Oral cancers can be
ccessed relatively easily. This makes oral cancer a candidate for
reatment by BNCT [14–17]. In this paper, we review the introduc-
ion of the principle of BNCT and the mechanism by which BNCT
xerts antitumor effects on oral SCC.
α particle
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Neutron  beam
Reactor 
ig. 3. The principle of boron neutron capture therapy (BNCT). BNCT is a two-component
ith a thermal neutron beam. 10B absorbs the neutrons and releases an (4He) particl
–10 m,  the effect depends on the maintenance of relatively high concentrations of 10B
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2.  Principles of BNCT
The  ﬁrst theoretical account of the biological effects and ther-
apeutic possibilities of BNCT was  published by Locher [18]. BNCT
is a two-component modality, in which boron-10 (10B)-enriched
compounds such as boronophenylalanine (BPA) and borocaptate
sodium (BSH) are administered, prior to irradiation with a ther-
mal neutron beam. 10B absorbs the neutrons and releases two
linear energy transfer particles, an (4He) particle and a lithium
(7Li) nucleus (Fig. 3). These products from the 10B (n, ) 7Li reac-
tion have path lengths in water of 5–10 m.  This suggests that
the effectiveness of BNCT depends on the maintenance of rela-
tively high concentrations of 10B in the tumor compared with the
surrounding normal tissues, and that BNCT potentially targets neo-
plastic tissue selectively [11–13]. Thermal neutrons are responsible
for the boron capture reaction, but epithermal neutrons are now
more generally used to improve the depth-dose proﬁle. It should
be also stated that boron captures thermal neutrons to produce
two high linear energy transfer (LET) particles, i.e. (4He) particle
and lithium (7Li) nucleus. However, they are also captured non-
selectively by tissue nitrogen and hydrogen to produce high LET
protons and low LET gamma  rays which are by deﬁnition not tumor
speciﬁc.
Thus, it is essential to elevate the intracellular boron concen-
tration in tumor cells, while maintaining low levels of 10B in
normal tissue. This results in a high tumor/normal tissue (T/N) ratio.
Another important factor is the use of nuclear reactors, because
the source of neutrons is limited to neutron beams derived from
nuclear reactors. Thus, the treatment can be done only in cer-
tain countries and areas. Reactor-derived neutrons are classiﬁed
according to their energies as thermal (En < 0.5 eV), epithermal
(0.5 eV < En < 10 keV), or fast (En > 10 keV). Thermal neutrons are
the most important for BNCT as they initiate the 10B (N, )7Li cap-
ture reaction. Because they have a limited depth of penetration,
epithermal neutrons, which lose energy and fall into the thermal
range as they penetrate tissues, are now preferred for clinical ther-
apy. Several nuclear reactors with good neutron beam quality have
been developed. These include the Massachusetts Institute of Tech-
nology reactor (MITR) in the USA, the clinical reactor at Studsvik
10 μm
Tumor 
cell
 modality, in which 10B-enriched compounds are administered, prior to irradiation
e and a lithium (7Li) nucleus. Since these products have path lengths in water of
 in the tumor compared with the surrounding normal tissue. Only tumor cells that
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Fig. 4. Surviving fraction of human oral SCC cells after in vitro boron neutron capture
therapy (BNCT). Oral SCC cells were incubated with boronophenylalanine (BPA) at
a 10B concentration of 50 ppm for 2 h to allow the incorporation of 10B. Thereafter,
they  were exposed to a neutron beam. Similarly, cells were exposed to a neutron
beam alone or gamma  ray. Thereafter, the colony-forming ability of the irradiated
cells  was  examined and the surviving fraction was  determined. The result indicates
that BPA-mediated BNCT is more effective than neutron alone and gamma ray.
Fig. 5. Effect of boron neutron capture therapy (BNCT) on the cell cycle. SAS cells were tre
cytometric analysis. From an analysis of DNA histograms, the percentages of cells in the su
cells was arrested at the G1 and G2 checkpoints, and sub-G1 cells showing apoptotic cell 
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cdc25
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BNCT
S
cdc2
phosphorylat ion
G2
M
apoptosis
mitotic  cell  deat h
repair
senescence
Fig. 6. Schematic presentation of cell-cycle arrest by boron neutron capture therapy (BNCT
the  phosphorylation of p53, up-regulation of p21, and down-regulation of Rb at 6 h after B
and  up-regulation of cyclin B1 were observed. Cleavage of PARP occurred from 6 h after BN
with G1 arrest in BNCT-treated cells.ernational 10 (2013) 9– 14 11
Medical AB in Sweden, the FiR1 clinical reactor in Helsinki, Finland,
the R2-0 High Flux Reactor at Petten in the Netherlands, the LVR-15
reactor at the Nuclear Research Institute in Rez, Czech Republic, the
Kyoto University Research reactor in Kumatori, Japan, JRR4 at the
Japan Atomic Energy Research Institute, and the RA-6 CNEA reac-
tor in Bariloche, Argentina [19]. However, MITR is no longer used.
Studsvik Medical has been decommissioned and Petten no longer
has a license to treat patients. Bariloche in Argentina is also not used
for patients now. Other nuclear reactors available for BNCT research
include TRIGA mark II reactor at University of Mainz in Germany,
the TRIGA MarkII reactor of the University of Pavia in Italy, RA-3
reactor at Buenos Aires in Argentina, Tsing Hua Open-pool reactor
(THOR) in Taiwan, and the Xi’an Pulsed Reactor (XAPR) in China
[20–24].
3. BNCT in oral SCC cell cultures
The mechanism of radiotherapy is dependent on the type of
LET. In low LET, the major effect is DNA damage, whereas high LET
acts directly to cut the DNA strand. Although conventional radi-
ation is effective against a variety of cancers, high LET radiation
such as carbon-ion irradiation and BNCT offers several potential
ated with BNCT or gamma rays at a physical dose of 6 Gy and then subjected to ﬂow
b-G1, G0/G1, S, and G2/M phases were evaluated. The cell cycle of the BNCT-treated
death appeared.
p21
p53
Rb
dephosphorylat ion DNA damage
BNCT
G0/G1
Cyclin  D/
CDK4,6
apoptosis
repair
G1 arres t
Rb
phosphorylat ion
). Immunoblot analysis of BNCT-treated oral squamous cell carcinoma cells revealed
NCT. Twelve hours after BNCT, the up-regulation of Wee1, phosphorylation of cdc2,
CT. This indicates the arrest at the G1 and G2 checkpoints and apoptosis associated
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Fig. 7. Effect of boron neutron capture therapy (BNCT) on the growth of tumors.
Group  1 ( ), 2 ( ) and 3 ( ) animals received a boronophenylalanine (BPA)
injection  and then neutron irradiation 1, 2, or 3 h later, respectively. The physical
dose  was  11.32 Gy. Group 4 ( ) and 5 ( ) animals received either BPA or neu-
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(
iron  irradiation alone. The tumor volume was markedly suppressed in animals that
eceived BNCT.
dvantages over X irradiation [25], including a reduction in the oxy-
en enhancement ratio with a proportionately greater killing effect
n hypoxic cells, less variation in cell cycle-related radiosensitivity,
nd less capability of repair of radiation injury. Thus, high LET radi-
tion has a higher relative biologic effectiveness, compared with X
rradiation and gamma irradiation (Fig. 2).
In BNCT, one important point to be clariﬁed is the incorpo-
ation of 10B into cells when BPA are used as 10B compounds.
e incubated oral SCC cells with BPA at a concentration of
0 ppm for 2 h. The cells were washed to remove unincorporated
ig. 8. Immunohistochemical staining of 5-bromo-2′-deoxyuridine (BrdU)-incorporated t
eutron  capture therapy (BNCT) at a dose of 11.32 Gy. One day later, tumor tissues were
essels, von Willebrand factor (vWF). The number of BrdU-positive tumor cells (arrows)
B).  Disintegration of tumor blood vessels (arrows) was observed in BNCT-treated tumors
n  C and D.ernational 10 (2013) 9– 14
compound and then exposed to thermal neutrons. The propor-
tion of cells capable of forming colonies decreased exponentially,
depending on the physical dose. The survival fraction in cells
treated with BPA-mediated BNCT was  lower than those of neutrons
alone and gamma  ray [26] (Fig. 4), indicating that BPA potentiated
the effect of neutron beam on cell survival. It can be stated that
the BPA-mediated BNCT shows stronger biological effect on cell
survival than low LET gamma  X-ray.
Cell death is categorized into two  types, intermediate death and
mitotic; the intermediate cell death being apoptosis. Gamma irra-
diation induces DNA damage and leads to cell-cycle arrest which
in eukaryotic cells protects the integrity of the genome. Arrest at
G1 permits repairs for replication, whereas arrest at G2 permits
repair of the genome prior to its mitotic segregation [27]. Further-
more, a signal transduction pathway that communicates signals
from DNA damage to the cell-cycle machinery involves the activa-
tion of many gene products including p53, p21, 14-3-3, ataxia
telangiectasia mutated, checkpoint kinase 1, Wee1, cell division
cycle 25 (cdc25), and cell division cycle 2 (cdc 2) to arrest the cell
cycle, thus providing cells with the critical time needed to repair
damaged DNA [28–34]. The effects of BPA-mediated BNCT on the
cell cycle of human oral SCC cells were examined at a physical dose
of 6 Gy. In the ﬂow-cytometric analysis of BNCT-treated cells, the
cell cycle was  arrested at the G1 and G2 checkpoints, and sub-G1
cells showing apoptotic cell death appeared (Fig. 5). Immunoblot
analysis revealed the phosphorylation of p53, up-regulation of p21,
and down-regulation of Rb at 6 h after BNCT. Twelve hours afterregulation of cyclin B1 were observed. Cleavage of poly(ADP-ribose)
polymerase (PARP), a marker of apoptosis, occurred from 6 h after
BNCT [26,35]. These results indicate that the early inhibitory effect
umor cells and tumor blood vessels. SAS tumor-bearing mice were treated by boron
 examined for the incorporation of BrdU and the expression of a marker of blood
 was  markedly reduced after BNCT (A) as compared with the unirradiated control
 (C), but not in unirradiated control tumors (D). Bars, 25 m in A and B, and 50 m
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f BNCT on the growth of human oral SCC cells can be ascribed to
rrest at the G1 and G2 checkpoints and apoptosis associated with
1 arrest (Fig. 6).
.  BNCT in oral cancer models
There  are two animal models for BNCT; the hamster cheek pouch
odel and the mouse oral SCC xenograft model. In the hamster
odel, a chemical carcinogen, 9,10-dimethyl-1,2-benzanthracene
DMBA), is applied repeatedly to cheek pouches to generate papil-
omatous SCCs. Using this model, the effects of BNCT on oral
arcinogenesis and growing tumors have been studied in Argentina
22,36–38]. At a dose of 300 mg/kg, BPA delivers 36.9 ± 17.5 ppm
f boron to tumor tissue with T/N and tumor/blood ratios of
.4 and 3.2, respectively. The total tumor dose was  estimated
o be 14.9 Gy-Eq and BNCT led to a complete remission by 15
ays post treatment in 78% of tumors and partial remission in
n additional 13% of tumors with virtually no damage to normal
issue.
In the oral SCC xenograft model, we injected BPA at a dose of
50 mg/kg intraperitoneally [39]. Two hours after the injection,
he 10B concentration in tumor was 16 ± 2 ppm and the T/N ratio
as 4.2. Tumors were then given neutron radiation 1, 2, and 3 h
ater at a physical dose of 11.32 Gy. In control animals that received
PA alone, the tumors continued to grow and were 1100% of the
nitial volume 21 days after the start of the experiment. Tumor
rowth in BNCT-treated animals was signiﬁcantly inhibited, irre-
pective of the interval between the BPA injection and neutron
rradiation. There was a signiﬁcant decrease as compared with
he BPA only group [40,41] (Fig. 7). All untreated animals died
ithin 50 days of the start of the experiment. Tumors in BNCT-
reated groups 1 (BPA 1 h) and 3 (BPA 3 h) decreased markedly,
ut showed regrowth after a period, and the animals had died by
ays 83 and 96, respectively. In contrast, those in group 2 animals
BPA 2 h) regressed completely and the mice survived the experi-
ental period of 120 days, indicating the importance of the interval
etween the BPA injection and neutron irradiation and the 10B con-
entration during neutron irradiation. It is concluded that BPA is
he most reliable compound, because of the selective incorporation
nto tumor cells and that BPA-mediated BNCT can cure oral SCC.
he T/N ratios in chemically induced hamster model and xenograft
odel were 2.4:1 and 4.2:1. The difference will clearly inﬂuence
he responses.
When tumors treated by BNCT were subjected to immuno-
istochemical staining, BNCT reduced the incorporation of
-bromo-2′-deoxyuridine (BrdU) into tumor cells, and induced the
nlargement and vacuolation of tumor cells. The disintegration of
lood vessels and dense inﬂammatory cell inﬁltration were also
bserved in the stroma of the tumor, but not surrounding nor-
al tissues [40] (Fig. 8). Thus, the disintegration of blood vessels
n tumor stroma may  contribute to tumor remission by BNCT.
.  Conclusion
BNCT is a novel form of radiotherapy. Accumulating data have
hown the effectiveness for patients who had been treated with
 full dose of conventional radiotherapy previously, because of
electivity of BNCT. However, this property is dependent on the
umor/normal tissue ratio in boron concentration attained. The
electivity is still partial. Basic research in vitro and in vivo revealed
he concentration of 10B and physical dose required, the efﬁciency
f high LET particles produced by born neutron reaction, and asso-
iated vascular alterations in the tumors. These ﬁndings must
e taken into consideration when the BNCT is used as an initial
[ernational 10 (2013) 9– 14 13
therapy  for oral cancer alone and in combination with conventional
therapy.
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